LifeStance Health Group (LFST) Stock Price, News & Analysis

Company Overview

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services. Clinicians at LifeStance employ a range of therapeutic approaches—such as cognitive behavioral therapy (CBT), dialectical behavior therapy (DBT), and trauma-informed care—to address conditions including anxiety, depression, attention-deficit/hyperactivity disorder (ADHD), and other mental health challenges. Telehealth options further enhance access for patients facing geographic or scheduling limitations.

LifeStance partners with health plans, employer-sponsored programs, and governmental payers to integrate its services into broader healthcare ecosystems. These collaborations facilitate in-network access through major insurance carriers and support employer wellness initiatives aimed at improving workforce mental health. Since its inception, the company has expanded both organically and through strategic acquisitions to establish a broad national footprint and meet the increasing demand for outpatient behavioral health services.

Key Stats

• Today's Range: $7.36 to $7.64
• 50-Day Range: $6.24 to $8.85
• 52-Week Range: $3.74 to $8.89
• Volume: 1.86 million shs
• Average Volume: 3.67 million shs
• Market Capitalization: $2.87 billion
• P/E Ratio: 123.50
• Dividend Yield: N/A
• Price Target: $9.75
• Consensus Rating: Moderate Buy

LifeStance Health Group Stock Analysis - MarketRank™

LifeStance Health Group scored higher than 87% of companies evaluated by MarketBeat, and ranked 73rd out of 868 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

LifeStance Health Group has received a consensus rating of Moderate Buy. The company's average rating score is 2.91, and is based on 2 strong buy ratings, 6 buy ratings, 3 hold ratings, and no sell ratings.

Upside Potential

LifeStance Health Group has a consensus price target of $9.75, representing about 31.6% upside from its current price of $7.41.

Amount of Analyst Coverage

LifeStance Health Group has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 75.00%

Earnings Growth

Earnings for LifeStance Health Group are expected to grow by 75.00% in the coming year, from $0.12 to $0.21 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of LifeStance Health Group is 123.50, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 44.53.

Price to Earnings Ratio vs. Sector

The P/E ratio of LifeStance Health Group is 123.50, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 24.09.

Price to Book Value per Share Ratio

LifeStance Health Group has a P/B Ratio of 1.90. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.29% of the float of LifeStance Health Group has been sold short.

Short Interest Ratio / Days to Cover

LifeStance Health Group has a short interest ratio ("days to cover") of 1.08, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in LifeStance Health Group has recently increased by 24.34%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

LifeStance Health Group does not currently pay a dividend.

Dividend Growth

LifeStance Health Group does not have a long track record of dividend growth.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.66

News Sentiment

LifeStance Health Group has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for LifeStance Health Group this week, compared to 3 articles on an average week.

Search Interest

Only 2 people have searched for LFST on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, LifeStance Health Group insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $55,048,226.00 in company stock.

Percentage Held by Insiders

6.60% of the stock of LifeStance Health Group is held by insiders.

Percentage Held by Institutions

85.50% of the stock of LifeStance Health Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/06/2026
• Today: 6/08/2026
• Next Earnings (Estimated): 8/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - OUTP/HM CRE
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:LFST
• CIK: 1845257
• Web: www.lifestance.com
• Phone: 602-767-2100
• Fax: N/A
• Employees: 10,961
• Year Founded: 2017

Price Target and Rating

• Average Price Target for LifeStance Health Group: $9.75
• High Price Target: $12.00
• Low Price Target: $8.00
• Potential Upside/Downside: +31.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.91
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.06
• Trailing P/E Ratio: 123.50
• Forward P/E Ratio: 61.75
• P/E Growth: N/A
• Net Income: $9.66 million
• Net Margins: 1.55%
• Pretax Margin: 2.25%
• Return on Equity: 1.56%
• Return on Assets: 1.07%

Debt

• Debt-to-Equity Ratio: 0.18
• Current Ratio: 1.48
• Quick Ratio: 1.48

Sales & Book Value

• Annual Sales: $1.42 billion
• Price / Sales: 2.02
• Cash Flow: $0.17 per share
• Price / Cash Flow: 44.05
• Book Value: $3.91 per share
• Price / Book: 1.90

Miscellaneous

• Outstanding Shares: 387,830,000
• Free Float: 362,237,000
• Market Cap: $2.87 billion
• Optionable: Optionable
• Beta: 1.19